{"organizations": [], "uuid": "1b0e1bc3c18d5077a7357cce24784a4c9f4b4296", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/09/20/104720912-AP_16230778829653.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/15837362/device/rss/rss.html", "section_title": "U.S. News", "url": "https://www.cnbc.com/2018/01/23/us-appeals-court-invalidates-johnson-johnson-patent-on-remicade.html", "country": "US", "domain_rank": 767, "title": "US appeals court upholds ruling invalidating Johnson & Johnson patent", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T18:09:00.000+02:00", "replies_count": 0, "uuid": "1b0e1bc3c18d5077a7357cce24784a4c9f4b4296"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/01/23/us-appeals-court-invalidates-johnson-johnson-patent-on-remicade.html", "ord_in_thread": 0, "title": "US appeals court upholds ruling invalidating Johnson & Johnson patent", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "johnson & johnson", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "u.s. circuit court of appeals for the federal circuit", "sentiment": "none"}, {"name": "j&j", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&Js ability to seek damages from Pfizer over its launch of a lower-cost version of the drug.\nThe U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent.\nRepresentatives of J&J and Pfizer did not immediately respond to requests for comment on the ruling.\nRemicade generated U.S. sales of $4.8 billion for J&J in 2016 but faces increased competition from cheaper \"biosimilar\" copycats, including Pfizer's version, which is sold in the U.S. under the name Inflectra.\nPfizer launched Inflectra in October 2016 after winning a set of rulings that invalidated J&J's patent.\nJ&J said at the time that it considered Pfizer's maneuver to be an at risk launch, meaning Pfizer would be liable for money damages to J&J if an appeals court reversed the rulings and upheld the patent.", "external_links": [], "published": "2018-01-23T18:09:00.000+02:00", "crawled": "2018-01-23T19:25:30.009+02:00", "highlightTitle": ""}